Clinical Trials · NCT02990845
Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 1/Phase 2
- Recruitment status
- Terminated
- Sponsor
- National Taiwan University Hospital
- Enrollment
- 16
- Start date
- Sep 2017
- Locations
- 1 site, Taiwan
- Primary endpoint
- The PFS rate at 8 months